Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 12/17/2016 |
| Start Date: | September 2013 |
| End Date: | November 2016 |
The purpose of this study is to investigate the role of the pulmonary vasculature in the
development and progression of chronic obstructive pulmonary disease (COPD). To accomplish
this, an inhaled prostacyclin (iloprost) will be given to patients with COPD and changes in
oxidative stress and lung volumes during exercise will be measured.
development and progression of chronic obstructive pulmonary disease (COPD). To accomplish
this, an inhaled prostacyclin (iloprost) will be given to patients with COPD and changes in
oxidative stress and lung volumes during exercise will be measured.
Chronic obstructive pulmonary disease (COPD), the 3rd leading cause of death in the US, is a
progressive disorder for which new treatments are urgently needed, as existing therapies are
focused primarily on symptom relief. Oxidative stress, in part arising from inducible nitric
oxide synthase (iNOS) released by the pulmonary vasculature, is critical for the development
and progression of COPD; a treatment strategy focused on the pulmonary vasculature is
hypothesized to be beneficial in COPD patients. This will be studied with the use of an
inhaled prostacyclin analogue, iloprost, which has been approved for pulmonary hypertension
and investigated in small studies of COPD patients. Potential mechanisms include reductions
in dynamic hyperinflation during exercise in COPD patients or improvements in oxidative
stress
progressive disorder for which new treatments are urgently needed, as existing therapies are
focused primarily on symptom relief. Oxidative stress, in part arising from inducible nitric
oxide synthase (iNOS) released by the pulmonary vasculature, is critical for the development
and progression of COPD; a treatment strategy focused on the pulmonary vasculature is
hypothesized to be beneficial in COPD patients. This will be studied with the use of an
inhaled prostacyclin analogue, iloprost, which has been approved for pulmonary hypertension
and investigated in small studies of COPD patients. Potential mechanisms include reductions
in dynamic hyperinflation during exercise in COPD patients or improvements in oxidative
stress
Inclusion Criteria:
- 40 years old or older
- Physician diagnosis of chronic obstructive pulmonary disease
- 10 or more pack-year smoking history
- FEV1/FVC <0.70
- FEV1 35-80% of predicted
Exclusion Criteria:
- Acute exacerbation of COPD within the last 30 days
- Pregnant or breast-feeding
- Contraindications to cardiopulmonary exercise testing
- Known intolerance or allergy to iloprost
- On oral corticosteroids (may be included if off for 7 days prior to testing)
- Supplemental oxygen need
- Known inflammatory disease other than COPD
- Active solid organ/hematologic malignancy
We found this trial at
1
site
New Orleans, Louisiana 70112
Principal Investigator: Matthew R Lammi, MD
Phone: 504-568-4634
Click here to add this to my saved trials
